Business Context and Reporting Period
Company: NeuroSense Therapeutics Ltd.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: April 2026 (Event date: April 6, 2026)
Context: This filing reports a material corporate event regarding intellectual property rights rather than a periodic financial report.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document serves solely to disclose a specific corporate event and does not contain financial statements.
Material Changes
- Intellectual Property: NeuroSense Therapeutics Ltd. was granted a Brazilian patent covering its PrimeC composition.
- Regulatory Impact: The first two paragraphs of the associated press release are incorporated by reference into the company's Registration Statements on Form S-8 and Form F-3.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, future outlook, management commentary on operations, or specific risk factors beyond the disclosure of the patent grant. No unusual items or contingencies are detailed in this specific report.
Investor Verification Checklist
- Verify the scope and validity of the Brazilian patent granted for the PrimeC composition.
- Review the full text of the press release (Exhibit 99.1) for details on the patent's commercial implications.
- Confirm the incorporation of this news into active Registration Statements (Form S-8 and Form F-3).